vTv Therapeutics Inc. Long Term Debt (Total)

Long Term Debt (Total) of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.


Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending September 29, 2019 was $1.36 Million (a -37.62% decrease compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) decreased by -78.47%
  • Annual Long Term Debt (Total) for 2018 was $6.33 Million (a -58.67% decrease from previous year)
  • Annual Long Term Debt (Total) for 2017 was $15.3 Million (a 38.51% increase from previous year)
  • Annual Long Term Debt (Total) for 2016 was $11.1 Million (a -69.3% decrease from previous year)
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of vTv Therapeutics Inc.

Most recent Long Term Debt (Total)of VTVT including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of vTv Therapeutics Inc.

vTv Therapeutics Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $1.36 $2.19 $4.01
2018 $6.33 $8.61 $10.86 $13.09 $6.33
2017 $15.32 $17.23 $18.52 $18.76 $15.32
2016 $11.06 $11.06
2015 $6.71
2014 $36.01
2013 $2.26 $2.27

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.